The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Retrospectively registered

Titles & IDs
Public title
Double blind, randomised cross-over trial of the efficacy of cranial electrotherapy stimulation on pain in fibromyalgia
Scientific title
The efficacy of cranial electrotherapy stimulation for the reduction of pain in fibromyalgia
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Fibromyalgia 243488 0
Condition category
Condition code
Alternative and Complementary Medicine 239788 239788 0 0
Other alternative and complementary medicine
Musculoskeletal 239828 239828 0 0
Other muscular and skeletal disorders

Study type
Description of intervention(s) / exposure
We intend to recruit 30 clinically diagnosed Fibromyalgia Syndrome (FMS) patients into a double blind, randomised, placebo
controlled, cross-over study with two conditions, a placebo/sham and a treatment condition. The Alpha-Stim -Registered Trademark - cranial electrotherapy stimulator will be used for both conditions. The Alpha-Stim SCS is a hand-held device which delivers a low-intensity electric microcurrent to the brain via small electrodes, which are attached to the earlobes. This product is Food and Drug Administration U.S.A (FDA) and Therapeutic Goods Administration Australia (TGA) approved. The stimulation unit will be set at 0.5 Hertz and 100 microamperes which in most individuals, does not produce any palpable physical sensation. The sham unit will not conduct any current.
After a session of training in use of the device, participants will self-administer treatment using the Alpha-Stim unit daily for a period of one hour per day over the course of three weeks. There is no 'wash-out' period between treatment conditions.
Intervention code [1] 237107 0
Treatment: Devices
Comparator / control treatment
Placebo treated using sham device.
Control group

Primary outcome [1] 240557 0
Pain Reduction

This outcome measures will be measured by tenderpoint count, visual analogue scales and self-report Fibromyalgia Impact Questionnaire (FIQ)
Timepoint [1] 240557 0
Baseline, 3 weeks and 6 weeks.
Secondary outcome [1] 257144 0
Anxiety Reduction)

Measured by Depression and Anxiety Symptoms questionnaire (DAS) and the Inventory of Depressive Symptoms (IDS)
Timepoint [1] 257144 0
Baseline, 3 weeks and 6 weeks.
Secondary outcome [2] 257145 0
Reduction of Insomnia

Quality of sleep measured by the Pittsburg Sleep Inventory
Timepoint [2] 257145 0
Baseline, 3 weeks and 6 weeks.
Secondary outcome [3] 257146 0
Impact of Illness - Fibromyalgia Impact Questionnaire
Timepoint [3] 257146 0
Baseline, 3 weeks and 6 weeks.
Secondary outcome [4] 257147 0
Reduction in Depressive Symptoms

Depression measured by Depression and Anxiety Symptoms questionnaire (DAS) and the Inventory of Depressive Symptoms (IDS)
Timepoint [4] 257147 0
Baseline, 3 weeks and 6 weeks.

Key inclusion criteria
Person's diagnosed with Fibromyalgia
Minimum age
18 Years
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
Persons under 18.
Pregnant women.

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The study will employ a double-blind, placebo-control, crossover design.
Patients who satisfy the criteria for inclusion in the trial and who agree to participate will undergo a randomisation procedure so as to be allocated to one of two groups. Allocation involved contacting the holder of the allocation schedule who was “off-site” or at central administration site. Depending on the sample characteristics, we may use a block randomisation or a minimisation procedure to allocate participants to ensure comparability of the groups on variables such as age, sex, disease activity
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Sequences will be generated using the random number generator in MS Excel.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?

Intervention assignment
Other design features
Not Applicable
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 237480 0
Name [1] 237480 0
Deakin University
Address [1] 237480 0
Burwood Hwy,
Burwood, VICTORIA 3125
Country [1] 237480 0
Primary sponsor type
Commercial sector/Industry
Pacific Medistim
Pacific Medistim Distributors Pty.Ltd.
Queensland, 4216. Australia
Secondary sponsor category [1] 236964 0
Name [1] 236964 0
Address [1] 236964 0
Country [1] 236964 0

Ethics approval
Ethics application status
Ethics committee name [1] 239603 0
Deakin University Human Research Ethics
Ethics committee address [1] 239603 0
Burwood Hwy
Burwood 3125
Ethics committee country [1] 239603 0
Date submitted for ethics approval [1] 239603 0
Approval date [1] 239603 0
Ethics approval number [1] 239603 0
EC 91-2009

Brief summary
We are conducting a study of a potential treatment (Alpha-Stim:Registered Trademark) for pain associated with fibromyalgia. We are looking for people who have been diagnosed with fibromyalgia who are willing to trial the Alpha-Stim: Registered Trademark Cranial Electrotherapy Stimulation (CES) device daily over a six week period.

If you do agree to participate, you will be required to attend the laboratory at Deakin Burwood Campus for three 2 hour sessions within the 6 week period of the study. The first of these sessions will be held before your first 3 weeks of CES treatment, the second after the first 3 weeks, and the third at the conclusion of your treatment. During each of these sessions, we will be measuring your levels of pain, anxiety, depression and quality of sleep using certain tests. You will be asked to fill out some questionnaires to establish the severity and impact of your symptoms. These questionnaires should take about 20 minutes to complete. We will seek information such as your age, gender and the length of time you have suffered from fibromyalgia. Pain will be measured using a device which applies light pressure to parts of the body, and a visual analogue scale, which is a questionnaire asking for your level of agreement with certain statements about your pain.
We will also measure some psychological and cognitive attributes. The tests being used are all standardized clinical measures and will be used to assess you at baseline (pre-treatment), in the middle of the 6 weeks and then again at the conclusion of the 6 week period (post-treatment).
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 30031 0
Address 30031 0
Country 30031 0
Phone 30031 0
Fax 30031 0
Email 30031 0
Contact person for public queries
Name 13278 0
Ms Melissa Seedy
Address 13278 0
Deakin University
Burwood Hwy
Burwood, VICTORIA 3125
Country 13278 0
Phone 13278 0
+61 3 9251-7749
Fax 13278 0
Email 13278 0
Contact person for scientific queries
Name 4206 0
Ms Melissa Seedy
Address 4206 0
Deakin University
Burwood Hwy
Burwood, VICTORIA 3125
Country 4206 0
Phone 4206 0
+61 3 9251-7749
Fax 4206 0
Email 4206 0

No information has been provided regarding IPD availability
Summary results
No Results